Technology & innovation

This archive covers technology and innovation breakthroughs that improve lives, protect the environment, and expand human possibility. From medical devices to clean energy tools, the stories here focus on what’s working and who’s making it happen.

Dentist's Hand Taking Saliva Test From Woman's Mouth

Hand-held test for breast cancer uses your saliva and gives accurate readings in 5 seconds

A handheld breast cancer screener developed by researchers in the U.S. and Taiwan can detect cancer biomarkers from a single drop of saliva in under five seconds — using a reusable circuit board that costs just $5 and paper test strips priced in pennies. Built on the same glucose-strip technology found in home diabetes kits, the device was designed specifically for clinics and communities where mammograms and MRIs aren’t an option. Lead author Hsiao-Hsuan Wan said the goal was to make screening possible where it simply hasn’t been before. Clinical trials and approvals still lie ahead, but if it gets there, early detection — one of medicine’s most powerful tools against breast cancer — could finally reach the millions of women long left out.

Colorful awareness ribbons representing multiple cancer types on pink background

New drug quadruples three-year survival rates for mesothelioma in international trial

Mesothelioma survival rates have quadrupled over three years thanks to a drug that starves tumors of a key nutrient, marking the first successful new treatment combination for the disease in 20 years. The international ATOMIC-meso trial, led by Queen Mary University of London and published in JAMA Oncology, found that patients receiving pegargiminase alongside standard chemotherapy were significantly more likely to be alive three years later. The drug works by depleting arginine in the bloodstream, cutting off a nutrient that mesothelioma cells cannot produce themselves. For a cancer caused by asbestos exposure that has historically offered patients months rather than years, this breakthrough represents a genuine turning point.

Aerial view of container ship

Decarbonization containers turn 78% of marine emissions into limestone in new pilot

A remarkable pilot project installed on a 787-ft. container ship has proven it’s possible to capture emissions from the smokestacks of cargo ships with 78% efficiency and convert the CO2 into limestone pebbles, which can be offloaded and sold. London startup Seabound, funded by a US$1.5-million grant from the UK Government, partnered up with global shipping company Lomar to install the carbon capture equipment on one of its older and dirtier-burning ships, a medium-sized vessel capable of carrying more than 3,200 shipping containers.

Depiction of nerve cells

Researchers discover an effective non-opioid treatment for nerve pain

Nerve pain affects an estimated one in ten adults in the U.S., and for many, nothing currently available offers real relief. A new compound called FEM-1689 reduced pain hypersensitivity in mice with diabetic and chemotherapy-induced neuropathy, working through a receptor entirely separate from opioid pathways and sidestepping addiction risk. The same cellular effect was observed in human neurons in the lab. All results remain pre-clinical, and many promising compounds fail before reaching patients. But the mechanistic clarity here puts a genuinely safer treatment for one of medicine’s most stubborn problems on much firmer ground.

Fluorescent-stained human chromosomes in vivid colors against a black background

Gene therapy hailed as ‘medical magic wand’ for hereditary swelling disorder

CRISPR gene editing has freed ten patients with hereditary angioedema from the sudden, sometimes life-threatening swelling attacks that shaped their daily lives, with several remaining attack-free for 18 months and counting after a single infusion. The therapy works by switching off a gene in liver cells, stopping the painful chain reaction at its source rather than just managing symptoms. One participant who used to have attacks every three weeks has needed no medication since. Doctors are now recruiting for a phase-three trial, building on the same Nobel-winning technology that recently produced an approved cure for sickle cell disease. For a rare condition long defined by unpredictability and fear, it’s a glimpse of what gene editing could mean for millions living with inherited illness worldwide.

Person having blood drawn

Breakthrough Alzheimer’s blood test could detect disease 15 years before symptoms emerge

A simple Alzheimer’s blood test trialed in Sweden can detect the disease’s biological signs up to 15 years before symptoms appear, matching the accuracy of a spinal tap in a study of 786 people. The test measures p-tau217, a protein that builds up in the blood as Alzheimer’s-related changes unfold in the brain. Researchers suggest it could one day be as routine as a cholesterol check for anyone over 50, replacing painful lumbar punctures and hard-to-access specialist scans. With one in three people born in the U.K. today expected to develop dementia, catching the disease early — while there’s still time to intervene — could transform how the world confronts one of its most feared illnesses.

Person receiving shot in the arm

Cancer vaccine with minimal side effects nearing Phase 3 clinical trials

A personalized cancer vaccine is heading into Phase 3 trials after a remarkable Phase 2 result: nearly 95% of advanced melanoma patients who received only the vaccine were still alive three years later. What makes Dr. Thomas Wagner’s TLPO vaccine so striking isn’t just the survival numbers — it’s the gentleness. Patients report little more than a sore arm and mild fatigue, a world away from the dread of chemotherapy. The vaccine is made from each patient’s own tumor cells, teaching their immune system to recognize cancer as the threat it is. If the larger trial holds up, it could reshape how we think about treating cancer everywhere — not as something to endure, but something to outsmart.

Artist's concept of a solar power satellite in place

First ever space-to-Earth solar power mission succeeds

Space-based solar power just cleared a milestone scientists have been chasing since the 1970s: a Caltech satellite spent a year in orbit, collected sunlight, and beamed it wirelessly back to a ground receiver on Earth. The SSPD-1 mission completed all three of its planned experiments, including testing an origami-inspired panel that unfolds without hinges and a purpose-built microwave transmitter. The appeal is simple — above the atmosphere, the Sun never sets, no clouds get in the way, and power could flow around the clock. Caltech’s team is honest that commercial-scale space solar is still years off, with cost and radiation durability to solve. But moving this idea from whiteboard to working demonstration brings humanity a real step closer to truly continuous clean energy.

Person receiving nasal spray

Novel nasal COVID-19 vaccine offers longer, better immunity than jabs

A nasal COVID-19 vaccine developed at Duke-NUS Medical School in Singapore is showing real promise: in hamster studies, it produced more central memory T cells than standard injections, hinting at protection that could last considerably longer. By delivering the vaccine right where the virus enters the body, researchers also saw stronger antibody responses against newly emerging variants. The team has filed a patent that covers other respiratory pathogens too, opening doors for future flu and RSV vaccines. Human trials are still ahead, but for anyone weary of frequent boosters — especially elderly and immunocompromised people — a needle-free shot offering broader, longer protection could meaningfully reshape how the world lives alongside evolving respiratory viruses.

Close-up illustration of pink cancer cells floating against a dark background

New protein test can detect 18 early stage cancers, scientists say

A new blood test can screen for 18 different cancers at once — covering every major organ in the body — using a single ordinary blood draw. Researchers at U.S. biotech firm Novelna found the test caught 93% of earliest-stage cancers in male samples and 84% in female samples, while also pinpointing which organ the cancer came from in more than 80% of cases. Instead of hunting for tumor DNA, the team analyzed proteins in blood plasma, picking up faint signals before a tumor does visible damage. Larger studies are still needed before it reaches clinics, but a cheap, accurate, broad screening tool would be a quiet revolution for global health — especially in places where late diagnosis is still the norm.